$ARMP

Armata Pharmaceuticals, Inc.

Armata Pharmaceuticals develops bacteriophage therapeutics, which use viruses that target and kill specific bacteria, for antibiotic-resistant and difficult-to-treat infections. Its proprietary technology combines phage discovery and engineering with specialized manufacturing capabilities. The company’s clinical-stage candidates include inhaled AP-PA02 for chronic pulmonary infections caused by Pseudomonas aeruginosa, including in non-cystic fibrosis bronchiectasis, and intravenous AP-SA02 for complicated Staphylococcus aureus bacteremia. Armata is also exploring AP-PA03 for acute P. aeruginosa infections, including ventilator-associated pneumonia. Armata’s programs are in clinical development, and it conducts clinical trials to assess the safety and efficacy of its product candidates as potential treatments alongside or as alternatives to antibiotics. Its development work also includes preclinical research and manufacturing process development. The company is headquartered in Los Angeles, California.

5
1
0

No SEC Form 4 filings for $ARMP in the last 30 days.

See all $ARMP insider activity →
Med

Armata Pharmaceuticals 3Q 2026: Revenue $3.17M, EPS ($0.24) — 10-Q Summary

Armata Pharmaceuticals reported 3Q 2026 revenue of $3.17M, up 173.6% YoY, and net income of $42.64M, reversing a prior-year loss. The gain was driven by higher grant revenue and a $69.6M increase in the fair value of the Convertible Loan, offset by increased expenses. FDA granted Breakthrough Therapy designation for AP-SA02, and Phase 3 preparation is underway.

Armata Pharmaceuticals receives two U.S. patents for therapies

Armata Pharmaceuticals (ARMP) received two U.S. patents for its bacteriophage therapies AP-SA02 and AP-PA02, protecting treatments for Staphylococcus aureus and Pseudomonas infections. The patents extend until 2041 and 2043, respectively. ARMP's portfolio includes 101 issued patents and 60 pending applications. AP-SA02 has FDA designations and a Phase 3 study planned for 2026.

ARMP sentiment & insider activity

Over the past 7 days, AlphAI's AI scored 6 news stories mentioning ARMP (Armata Pharmaceuticals, Inc.). Coverage has skewed bullish: 5 bullish, 1 neutral, and 0 bearish.

Recent ARMP coverage spans technology, corporate actions and earnings.

What's driving ARMP

AlphAI scores every news story that mentions ARMP with an AI model for sentiment and relevance, and aggregates insider trades from Armata Pharmaceuticals, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $ARMP

Score

Armata Pharmaceuticals receives two U.S. patents for therapies

Armata Pharmaceuticals (ARMP) received two U.S. patents for its bacteriophage therapies AP-SA02 and AP-PA02, protecting treatments for Staphylococcus aureus and Pseudomonas infections. The patents extend until 2041 and 2043, respectively. ARMP's portfolio includes 101 issued patents and 60 pending applications. AP-SA02 has FDA designations and a Phase 3 study planned for 2026.

$ARMPMedContract· $3.7M

Armata Pharmaceuticals Receives $3.7 Million in Additional Non-Dilutive Funding from U.S. Department of War to Support Advancement of AP-SA02 Phase 3…

Armata Pharmaceuticals, Inc. (ARMP) filed an SEC Form 8-K — Other Events. Exhibit 99.1 Armata Pharmaceuticals Receives $3.7 Million in Additional Non-Dilutive Funding from U.S. Department of War to Support Advancement of AP-SA02 Phase 3 Development Initial Phase 3-focused funding to support advancement of AP-SA02 in complicated Staphylococcus aureus ba

ARMP Stock Draws Bullish Focus After New Phage Breakthrough

Armata Pharmaceuticals Inc. (ARMP) stock rose 11.52% on September 14, 2026, driven by positive sentiment and a new peer-reviewed study on its therapeutic bacteriophage Ar-KM. The company's AP-PA02 therapy has completed Phase 2 trials, and the study provides mechanistic insights, reducing perceived development risk. Despite negative profitability and low revenue, traders are focused on the company's catalysts and momentum.

$ARMPHighAI 8/10

Armata Pharmaceuticals stock rises on FDA breakthrough designation

Armata Pharmaceuticals (ARMP) shares rose 8% after the FDA granted Breakthrough Therapy designation to AP-SA02, a treatment for complicated bacteremia caused by S. aureus. The designation is based on Phase 1b/2a study data showing 100% clinical response in treated patients. The company aims to develop bacteriophage therapeutics for resistant bacterial infections.

$ARMPHighAI 9/10Clinical / regulatory

Armata Pharmaceuticals Receives U.S. FDA Breakthrough Therapy Designation for AP-SA02

Armata Pharmaceuticals, Inc. (ARMP) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 Armata Pharmaceuticals Receives U.S. FDA Breakthrough Therapy Designation for AP-SA02 Designation is driven by compelling Phase 2 clinical data in patients with complicated Staphylococcus aureus bacteremia showing AP-SA02 may offer substantial improvement over availa

Armata Pharmaceuticals Advances Phage Therapy Research With New Ar-KM Publication

Armata Pharmaceuticals (ARMP) published research in the Journal of Molecular Biology detailing structural insights into Ar-KM, a bacteriophage targeting Pseudomonas aeruginosa. The study could aid in developing next-gen antibacterial therapies. ARMP's AP-PA02 program, using Ar-KM, has completed Phase 2 trials. The company is also expanding structural biology work to other phages. ARMP stock closed at $5.53, up 4.73%, and is down 2.35% in pre-market trading.

$ARMPMedAI 8/10

Armata Pharmaceuticals Announces Financial Results for the Second Quarter 2026 and Provides a Corporate Update

Armata Pharmaceuticals (NYSE American: ARMP) reported Q2 2026 results for the quarter ended June 30, 2026, with $2.5M grant and award revenue, R&D of about $7.6M, G&A of about $5.2M, and an operating loss of about $10.3M. The company said it submitted the Phase 3 protocol for AP-SA02 to the FDA, received Fast Track and an agreed pediatric study plan, and received an additional $2.5M non-dilutive DoD funding.

$ARMPMedEarnings

Armata Pharmaceuticals Announces Financial Results for the Second Quarter 2026 and Provides a Corporate Update

Armata Pharmaceuticals, Inc. (ARMP) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 ​ Armata Pharmaceuticals Announces Financial Results for the Second Quarter 2026 and Provides a Corporate Update ​ LOS ANGELES, Calif., August 12, 2026 - Armata Pharmaceuticals, Inc. (NYSE American: ARMP) (“Armata” or the “Company”), a late clinical-stage biotechnolo

Related tickers